Olivier Mir

机构：Amgen (United States), Université Paris-Saclay, Institut Gustave Roussy · ORCID：0000-0002-6761-4002

发表论文 551 篇 · 总被引 16598 次 · h-index 65

代表论文

• Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib (2023 · Annals of Oncology · 被引 45)
• Sex differences in the pharmacokinetics of anticancer drugs: a systematic review (2024 · ESMO Open · 被引 40)
• Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial (2025 · The Lancet · 被引 16)
• Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors (2024 · Cancer Research · 被引 7)
• Serotonin reuptake inhibitors improve muscle stem cell function and muscle regeneration in male mice (2024 · Nature Communications · 被引 7)
• Intraoperative motive for incomplete resection in primary retroperitoneal sarcoma (2023 · The French Journal of Urology · 被引 4)